^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mirabegron

    i
    Other names: YM178, YM-178
    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    β3 adrenergic receptor agonist
    Associations

    News

    Trials
    23d
    Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer (ChiCTR2500113415)
    P2, N=20, Not yet recruiting, Obstetrics and Gynecology Hospital, Fudan University; Obstetrics and Gynecology Hospital, Fudan University
    New P2 trial
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • mirabegron
    1m
    SQUARE PD: Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease (clinicaltrials.gov)
    P4, N=146, Not yet recruiting, VA Office of Research and Development | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    |
    mirabegron
    2ms
    Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion (clinicaltrials.gov)
    P4, N=500, Not yet recruiting, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
    New P4 trial
    |
    mirabegron
    2ms
    TRIUMPH: TReating Incontinence for Underlying Mental and Physical Health (clinicaltrials.gov)
    P4, N=270, Recruiting, University of California, San Francisco | Trial completion date: Jan 2027 --> Aug 2027 | Trial primary completion date: Nov 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    mirabegron
    3ms
    Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Obstetrics & Gynecology Hospital of Fudan University
    New P2 trial
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • mirabegron
    3ms
    Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: Mar 2026 --> Mar 2030 | Trial primary completion date: Mar 2026 --> Mar 2030
    Trial completion date • Trial primary completion date
    |
    mirabegron
    5ms
    Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (clinicaltrials.gov)
    P3, N=120, Recruiting, Mansoura University
    New P3 trial
    |
    mirabegron
    5ms
    BEST: Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence (clinicaltrials.gov)
    P4, N=432, Recruiting, Women and Infants Hospital of Rhode Island | Trial completion date: Jul 2027 --> Aug 2030
    Trial completion date
    |
    mirabegron
    5ms
    SQUARE PD: Sequential Multiple Assignment Randomized Trial to Treat Urinary Symptoms in Parkinson Disease (clinicaltrials.gov)
    P4, N=146, Not yet recruiting, VA Office of Research and Development
    New P4 trial
    |
    mirabegron
    6ms
    The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial (clinicaltrials.gov)
    P3, N=220, Not yet recruiting, Far Eastern Memorial Hospital
    New P3 trial
    |
    mirabegron
    7ms
    RAISE BP: Using Mirabegron to Increase BP in Patients With POTS (clinicaltrials.gov)
    P2, N=20, Completed, Cedars-Sinai Medical Center | Recruiting --> Completed | Trial completion date: Nov 2026 --> Jul 2025 | Trial primary completion date: Nov 2025 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    mirabegron
    8ms
    A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity (clinicaltrials.gov)
    P3, N=7, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting | N=10 --> 7
    Enrollment closed • Enrollment change
    |
    mirabegron